Phase III study of PD-1 checkpoint inhibitor cemiplimab as monotherapy for advanced or metastatic non-small cell lung cancer halted due to early signs of significant improvement in overall survival

The Independent Data Monitoring Committee halted the trial, which had recruited patients who tested positive for PD-L1 in more than 50% of tumour cells, after a decrease in relative risk of death by 32.4% was seen with cemiplimab compared to chemotherapy.

SPS commentary:

Cemiplimab monotherapy is currently licensed for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.


Biospace Inc.